Sanofi-Aventis engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its pharmaceutical activity specializes in thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system, and internal medicine areas. The company's products include Plavix, an anti-platelet agent for various atherothrombotic conditions; Lovenox, a low molecular weight heparin for deep vein thrombosis and unstable angina, and non-Q-wave myocardial infarction; Aprovel and Tritace for hypertension treatments; Lantus, an analog insulin and Amaryl, a sulfonylurea for metabolic disorders; Acomplia for obese patients with type 2 diabetes; Taxotere, a taxane derivative representing a therapy in various cancer types; and Eloxatine, a platinum agent for treating metastatic colorectal cancer.

Acquired Companies: Genzyme Corp., Canderm Pharma Inc, Sanofi-Synthelabo, Merial Ltd., TargeGen Inc., Acambis Plc, BMP Sunstone Corp., Centelion SAS, Fovea Pharmaceuticals SA, Aventis, Topaz Pharmaceuticals, Zentiva N.V., Chattem, Inc., Nepentes SA , VaxDesign Corp.